Amarin Corp Plc (AMRN)

[Dancing in the dark]

"Evidence could be carefully collected from various sources as to how generic sales infringe on the reduce it patents
The generics will of course be aware of this risk to them and it may colour their enthusiasm."

Evidence is readily available. This exercise could be fairly simple. Once generic icosapent ethyl Rxs exceed a threshold that accounts maximum treatable population of persons with triglycerides > 500 (reduced by lovaza and generic lovaza Rxs), then the generic icosapent ethyl manufacturers are producing a product intended to be used to treat an indication other than their skinny label.

https://www.iqvia.com/locations/united-states/solutions/commercial-operations/essential-information/prescription-information